Sinclair Pharma plc, the specialty pharmaceutical company, announced that its French subsidiary CS Dermatologie (CSD) has acquired the Fazol brand in France, Morocco, Algeria and Tunisia, from Janssen Pharmaceutica NV.

Fazol is a French market leader in topical anti-fungal products. It generates an annual turnover of more than €3m and is currently one of the largest single-brand contributions to the revenues of CSD.

CSD has produced and marketed Fazol in France, Morocco, Algeria and Tunisia under an exclusive licence agreement with Janssen since 2003. The complete acquisition of the brand in these territories means that CSD will be able to expand the Fazol range and benefit from substantially improved margins, worth more than €400,000 annually, additional to existing margin, at current sales levels.

Didier Rase, President of CSD commented, "In addition to improving our conditions of supply, this new contract means we will take full ownership of this flagship brand. We look forward to developing the commercial opportunity for Fazol."

Dr Michael Flynn, CEO of Sinclair Pharma plc, added: "The acquisition of the Fazol brand contributes to the continued expansion of CSD in the French dermatology market. CSD is contributing substantially to the Sinclair group and we are very pleased with the integration into our international operations. Atopiclair, our product for atopic dermatitis, was launched by CSD in February 2007, and we have also started to export their proprietary Dermo-Cosmetic products."

Sinclair Pharma plc is an international specialty pharmaceutical company. It has a growing sales and marketing operation that is already present in France, Italy, UK, Spain and Portugal, and a complementary marketing partner network that spans more than 65 countries.